https://scholars.lib.ntu.edu.tw/handle/123456789/633185
標題: | Pimecrolimus for the Treatment of Atopic Dermatitis in Infants: An Asian Perspective | 作者: | CHIA-YU CHU Yao, Tsung-Chieh Shih, I-Hsin Yang, Chin-Yi Chin, Chan Lee Ibrahim, Sabeera Begum Binti Kader Thevarajah, Suganthi Fon, Leong Kin Ho, Marco Hok-Kung Mo, Chow Chung Yu, Chow Pok Loo, Steven King-Fan Luger, Thomas |
關鍵字: | Asian population; Atopic dermatitis; Infants; Pimecrolimus; Topical calcineurin inhibitor | 公開日期: | 三月-2023 | 卷: | 13 | 期: | 3 | 來源出版物: | Dermatology and therapy | 摘要: | Atopic dermatitis (AD) is a common chronic, multisystem inflammatory skin disease in pediatric patients. There has been an increase in the incidence of AD in the pediatric population of the Asia-Pacific region. Studies have shown that genetic, epigenetic, environmental and cultural factors may lead to differences in the clinical manifestation and prevalence of AD between races. Early treatment of AD is necessary to prevent the atopic march leading to comorbidities such as asthma and allergic rhinitis. Topical corticosteroids (TCS) are used as first-line therapy for the treatment of AD, but their long-term usage poses a risk to the patient's health. Pimecrolimus (1%) is a topical calcineurin inhibitor (TCI) that is indicated for the treatment of mild to moderate AD. Pimecrolimus has no apparent increase in adverse events compared to TCS, and it causes less of a burning sensation than tacrolimus. The safety and efficacy of pimecrolimus has been established through various clinical trials; yet, in many Asian countries, the use of pimecrolimus in infants is still restricted due to safety concerns. Based on the available evidence, the expert panel recommends pimecrolimus in infants between 3 months and 2 years of age in the Asian population. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/633185 | ISSN: | 2193-8210 | DOI: | 10.1007/s13555-022-00886-9 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。